Sagimet Biosciences Inc.

SGMT · Nasdaq · United States

Share price · SGMT

$10.11-0.47 (-4.44%) 3M

close as of 2026-11-18 · 24h delayed · vol 933K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SGMT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 24 Sep 2026-12.6%
  2. 14 Aug 2026+13.7%
  3. 5 Aug 2026+8.1%
  4. 4 Aug 2026+11.7%
  5. 27 Apr 2026+38.6%
  6. 15 Apr 2026+9.6%

    Nothing announced by SGMT that day or the session before.

  7. 8 Apr 2026+10.0%
  8. 26 Mar 2026+10.6%

    Nothing announced by SGMT that day or the session before.

  9. 24 Feb 2026+12.1%
  10. 29 Jan 2026-8.5%

Share of unusual movement by asset

For each asset, the share of SGMT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Denifanstat
events and moves
94%
Other company news (earnings, financing, releases naming no asset)—19%
Sessions with no dated event—77%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Fatty acid synthase (FASN) · FASNSmall molecule
MASH / NASHGlioblastoma
Recurrent Glioblastoma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
DenifanstatPhase 3Acne Vulgaris
Est. primary completion 2027-08 · NCT07863193 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 December 2025Filing acceptedDenifanstatNMPA accepts denifanstat acne NDA
CN, NMPA · Ascletis Pharma · Source ↗
4 June 2025Topline resultDenifanstatChina phase III acne topline
Ascletis Pharma · Source ↗

Financial reports

Quarterly & interim (14)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$16M$111M+ $125M short-term inv.$19M-$12M operating cash flowreport ↗
View 13 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$12M$166M+ $74M short-term inv.$14M-$11M operating cash flowreport ↗
2026-Q1—$7.0M$37M+ $68M short-term inv.$11M-$8.6M operating cash flowreport ↗
2025-Q3—$9.7M$33M+ $84M short-term inv.$13M-$10M operating cash flowreport ↗
2025-Q2—$7.3M$42M+ $83M short-term inv.$10M-$9.1M operating cash flowreport ↗
2025-Q1—$15M$65M+ $80M short-term inv.$18M-$15M operating cash flowreport ↗
2024-Q3—$13M$77M+ $75M short-term inv.$15M-$20M operating cash flowreport ↗
2024-Q2—$6.3M$75M+ $70M short-term inv.$8.1M-$5.6M operating cash flowreport ↗
2024-Q1—$5.3M$177M+ $17M short-term inv.$6.6M-$6.2M operating cash flowreport ↗
2023-Q3$2.0M$5.0M$102M+ $0 short-term inv.$6.3M-$3.9M operating cash flowreport ↗
2023-Q2—$4.7M$19M+ $0 short-term inv.$6.8M-$5.7M operating cash flowreport ↗
2023-Q1—$4.5M$12M$6.6M-$7.1M operating cash flowreport ↗
2022-Q3—$6.8M$2.2M$7.5M-$6.2M operating cash flowreport ↗
2022-Q2—$6.4M$4.5M$7.1M$0 operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$39M$35M+ $78M short-term inv.$13M-$46M operating cash flowreport ↗

Sagimet Biosciences reported a full-year 2025 net loss of $51.04M, with revenue not disclosed. Research and development expense was $39.05M, up 1.6% YoY. Cash, cash equivalents and marketable securities totaled $113.1M as of December 31, 2025.

The company completed a Phase 1 pharmacokinetic trial of denifanstat combined with resmetirom and plans to initiate a Phase 2 proof-of-concept trial in F4 MASH patients in the second half of 2026. A first-in-human Phase 1 trial of the FASN inhibitor TVB-3567 is ongoing, with a Phase 2 acne trial anticipated in 2026. License partner Ascletis reported positive topline results from an open-label Phase 3 acne trial, and China's NMPA accepted an NDA for denifanstat for moderate to severe acne. Sagimet also secured a global, exclusive license to TAPI's resmetirom API forms for a potential fixed-dose combination.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$38M$76M+ $75M short-term inv.$11M-$42M operating cash flowreport ↗
2023-FY$2.0M$20M$75M+ $20M short-term inv.$7.0M-$24M operating cash flowreport ↗
2022-FY—$25M$0.2M+ $32M short-term inv.$7.6M-$24M operating cash flowreport ↗
2021-FY——$57M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 9 sales ($4.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-14Kemble George · directorOption exercise326,618$6.36$2.1MForm 4
2026-08-14Kemble George · directorOption exercise24,369$6.36$155KForm 4
2026-08-14Kemble George · directorOpen-market sale350,987$10.23$3.6MForm 4
2026-08-14Kemble George · directorOption exercise (derivative)326,618——Form 4
2026-08-14Kemble George · directorOption exercise (derivative)24,369——Form 4
2026-08-11Kemble George · directorOption exercise9,751$6.36$62KForm 4
2026-08-11Kemble George · directorOption exercise10,455$6.36$66KForm 4
2026-08-11Kemble George · directorOpen-market sale20,206$9.95$201KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 87 reporting institutions held 13.4M shares ($68.6M).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC1,098,919$5.7M
2Woodline Partners LP1,000,943$5.2M
3MARSHALL WACE, LLP966,253$5.0M
4BAKER BROS. ADVISORS LP952,996$5.0M
5Affinity Asset Advisors, LLC868,020$4.5M
6MILLENNIUM MANAGEMENT LLC862,303$4.5M
7BlackRock, Inc.799,943$4.2M
8HHLR ADVISORS, LTD.724,800$3.8M
9RENAISSANCE TECHNOLOGIES LLC625,469$3.3M
10D. E. Shaw & Co., Inc.411,570$2.2M
11Blue Owl Capital Holdings LP333,877$1.7M
12RAYMOND JAMES FINANCIAL INC317,550$1.7M
13GEODE CAPITAL MANAGEMENT, LLC309,522$1.6M
14Hudson Bay Capital Management LP303,223$1.6M
15BRIDGEWAY CAPITAL MANAGEMENT, LLC299,641$1.6M